292 related articles for article (PubMed ID: 14696762)
1. Tacrolimus-associated hemolytic uremic syndrome: a case analysis.
Lin CC; King KL; Chao YW; Yang AH; Chang CF; Yang WC
J Nephrol; 2003; 16(4):580-5. PubMed ID: 14696762
[TBL] [Abstract][Full Text] [Related]
2. A case of late onset cyclosporine-induced hemolytic uremic syndrome resulting in renal graft loss.
Katafuchi R; Saito S; Ikeda K; Hirano T; Yanase T; Nakashima K; Fujimi S
Clin Transplant; 1999; 13 Suppl 1():54-8. PubMed ID: 10751058
[TBL] [Abstract][Full Text] [Related]
3. Increased early rejection rate after conversion from tacrolimus in kidney and pancreas transplantation.
Barone GW; Ketel BL; Abul-Ezz SR; Lightfoot ML
JOP; 2002 Mar; 3(2):49-53. PubMed ID: 11884766
[TBL] [Abstract][Full Text] [Related]
4. Successful treatment of hemolytic uremic syndrome after liver-kidney transplantation.
Gatti S; Arru M; Reggiani P; Como G; Rossi F; Fassati LR; Ponticelli C
J Nephrol; 2003; 16(4):586-90. PubMed ID: 14696763
[TBL] [Abstract][Full Text] [Related]
5. Tacrolimus as secondary intervention vs. cyclosporine continuation in patients at risk for chronic renal allograft failure.
Waid T;
Clin Transplant; 2005 Oct; 19(5):573-80. PubMed ID: 16146546
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results.
Krämer BK; Montagnino G; Del Castillo D; Margreiter R; Sperschneider H; Olbricht CJ; Krüger B; Ortuño J; Köhler H; Kunzendorf U; Stummvoll HK; Tabernero JM; Mühlbacher F; Rivero M; Arias M;
Nephrol Dial Transplant; 2005 May; 20(5):968-73. PubMed ID: 15741208
[TBL] [Abstract][Full Text] [Related]
7. Spectrum of surgical complications after simultaneous pancreas-kidney transplantation in a prospectively randomized study of two immunosuppressive protocols.
Steurer W; Malaise J; Mark W; Koenigsrainer A; Margreiter R;
Nephrol Dial Transplant; 2005 May; 20 Suppl 2():ii54-62. PubMed ID: 15814551
[TBL] [Abstract][Full Text] [Related]
8. Graft failure due to hemolytic uremic syndrome recurrence.
Iaria G; Iorio B; Anselmo A; De Luca L; Tariciotti L; Ielpo B; Muzi F; Lucchesi C; D'Andria D; Orlando G; Del Poeta G; Poggi E; Piazza A; Tisone G
Transplant Proc; 2006 May; 38(4):1020-1. PubMed ID: 16757250
[TBL] [Abstract][Full Text] [Related]
9. Posttransplantation calcineurin inhibitor-induced hemolytic uremic syndrome: single-center experience.
Said T; Al-Otaibi T; Al-Wahaib S; Francis I; Nair MP; Halim MA; El-Sayed A; Nampoory MR
Transplant Proc; 2010 Apr; 42(3):814-6. PubMed ID: 20430179
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcome after conversion to FK 506 (tacrolimus) therapy for acute graft-versus-host disease resistant to cyclosporine or for cyclosporine-associated toxicities.
Furlong T; Storb R; Anasetti C; Appelbaum FR; Deeg HJ; Doney K; Martin P; Sullivan K; Witherspoon R; Nash RA
Bone Marrow Transplant; 2000 Nov; 26(9):985-91. PubMed ID: 11100278
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors and early resumption of cyclosporin A in renal allograft recipients with thrombotic microangiopathy and hemolytic uremic syndrome.
Wiener Y; Nakhleh RE; Lee MW; Escobar FS; Venkat KK; Kupin WL; Mozes MF
Clin Transplant; 1997 Jun; 11(3):157-62. PubMed ID: 9193835
[TBL] [Abstract][Full Text] [Related]
12. Thrombotic microangiopathy in United States long-term dialysis patients.
Perkins RM; Reynolds JC; Ahuja TS; Reid T; Agodoa LY; Bohen EM; Yuan CM; Abbott KC
Nephrol Dial Transplant; 2006 Jan; 21(1):191-6. PubMed ID: 16204286
[TBL] [Abstract][Full Text] [Related]
13. Follow-up of kidney graft recipients with cyclosporine-associated hemolytic-uremic syndrome and thrombotic microangiopathy.
Bren A; Pajek J; Grego K; Buturovic J; Ponikvar R; Lindic J; Knap B; Vizjak A; Ferluga D; Kandus A
Transplant Proc; 2005 May; 37(4):1889-91. PubMed ID: 15919494
[TBL] [Abstract][Full Text] [Related]
14. Shiga toxin-associated hemolytic uremic syndrome: absence of recurrence after renal transplantation.
Ferraris JR; Ramirez JA; Ruiz S; Caletti MG; Vallejo G; Piantanida JJ; Araujo JL; Sojo ET
Pediatr Nephrol; 2002 Oct; 17(10):809-14. PubMed ID: 12376808
[TBL] [Abstract][Full Text] [Related]
15. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
Bumbea V; Kamar N; Ribes D; Esposito L; Modesto A; Guitard J; Nasou G; Durand D; Rostaing L
Nephrol Dial Transplant; 2005 Nov; 20(11):2517-23. PubMed ID: 15985508
[TBL] [Abstract][Full Text] [Related]
16. [Hemolytic-uremic syndrome following kidney transplantation: prognostic factors].
Candinas D; Keusch G; Schlumpf R; Burger HR; Gmür J; Largiadèr F
Schweiz Med Wochenschr; 1994 Oct; 124(41):1789-99. PubMed ID: 7973505
[TBL] [Abstract][Full Text] [Related]
17. Rejection after simultaneous pancreas-kidney transplantation.
Arbogast H; Malaise J; Illner WD; Tarabichi A; Dieterle C; Landgraf R; Land W;
Nephrol Dial Transplant; 2005 May; 20 Suppl 2():ii11-7, ii62. PubMed ID: 15814544
[TBL] [Abstract][Full Text] [Related]
18. Relative nephroprotection during Escherichia coli O157:H7 infections: association with intravenous volume expansion.
Ake JA; Jelacic S; Ciol MA; Watkins SL; Murray KF; Christie DL; Klein EJ; Tarr PI
Pediatrics; 2005 Jun; 115(6):e673-80. PubMed ID: 15930195
[TBL] [Abstract][Full Text] [Related]
19. Duration of end-stage renal disease and kidney transplant outcome.
Goldfarb-Rumyantzev A; Hurdle JF; Scandling J; Wang Z; Baird B; Barenbaum L; Cheung AK
Nephrol Dial Transplant; 2005 Jan; 20(1):167-75. PubMed ID: 15546892
[TBL] [Abstract][Full Text] [Related]
20. 12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus.
Levy G; Grazi GL; Sanjuan F; Wu Y; Mühlbacher F; Samuel D; Friman S; Jones R; Cantisani G; Villamil F; Cillo U; Clavien PA; Klintmalm G; Otto G; Pollard S; McCormick PA
Liver Transpl; 2006 Oct; 12(10):1464-72. PubMed ID: 17004259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
